Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Bimatoprost BOS | 0.1 mg/ml | Eye drops, solution · Ophthalmic use | 1 Dropper Container | SAR 31.15 | Generic · Prescription | Boston Oncology Arabia | Valid |
| LUMIGAN 0.1MG/ML EYE DROPS | 0.1 mg/ml | Eye drops, solution · Ophthalmic use | 1 Dropper Container | SAR 39.35 | NCE · Prescription | ABBVIE Deutschland GmbH | Valid |
| LUMIGAN 0.3MG - ML EYE DROPS | 0.3 % | Eye drops, solution · Ocular use | 1 Dropper Container | SAR 56.20 | NCE · Prescription | ALLERGAN PHARMACEUTICALS LTD | Withdrawn by MAH · Not Marketed |
OPEN ANGLE GLUCOMA
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LATISSE | 0.03% | solution/drops · topical | ABBVIE | Prescription | 24 Dec 2008 |
| LUMIGAN | 0.01% | solution/drops · ophthalmic | ABBVIE | Prescription | 31 Aug 2010 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | SANDOZ | Prescription | 5 May 2015 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | APOTEX | Prescription | 20 Jul 2015 |
| BIMATOPROST | 0.03% | solution/drops · topical | SANDOZ | Prescription | 19 Apr 2016 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | GLAND | Prescription | 22 Mar 2019 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | ALEMBIC | Prescription | 12 Apr 2019 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | SOMERSET THERAPS LLC | Prescription | 19 Jun 2019 |
| BIMATOPROST | 0.03% | solution/drops · topical | ALEMBIC | Prescription | 21 Jan 2020 |
| DURYSTA | 10MCG | implant · ophthalmic | ABBVIE | Prescription | 4 Mar 2020 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | MICRO LABS | Prescription | 8 Sep 2020 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | EUGIA PHARMA | Prescription | 6 Oct 2022 |
| BIMATOPROST | 0.01% | solution/drops · ophthalmic | MANKIND PHARMA | Prescription | 17 Mar 2025 |
| ZOLYMBUS | 0.01% | gel · ophthalmic | THEA PHARMA | Prescription | 9 Sep 2025 |
| BIMATOPROST | 0.01% | solution/drops · ophthalmic | AMNEAL | Prescription | 22 Sep 2025 |
| LUMIGAN | 0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution/drops · ophthalmic | ABBVIE | Discontinued | 16 Mar 2001 |
| BIMATOPROST | 0.03% | solution/drops · topical | APOTEX | Discontinued | 1 Dec 2014 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | LUPIN | Discontinued | 20 Feb 2015 |
| BIMATOPROST | 0.03% | solution/drops · topical | HIKMA PHARMS | Discontinued | 9 Oct 2018 |
| BIMATOPROST | 0.03% | solution/drops · ophthalmic | HIKMA PHARMS | Discontinued | 8 Nov 2018 |
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
Indicated for the reduction of intraocular pressure (IOP) in adults with open angle glaucoma (OAG) or ocular hypertension (OHT) who are unsuitable for topical IOP-lowering medications.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-BIMATOPROST RC | 02403013 | 0.01 % / W/V | SOLUTION · OPHTHALMIC | APOTEX INC |
| BIMATOPROST RC | 02529580 | 0.01 % / W/V | SOLUTION · OPHTHALMIC | JUNO PHARMA CANADA INC. |
| JAMP BIMATOPROST SOLUTION RC | 02565773 | 0.01 % / W/V | SOLUTION · OPHTHALMIC | JAMP PHARMA CORPORATION |
| LATISSE | 02350939 | 0.03 % / W/V | SOLUTION · TOPICAL | ABBVIE CORPORATION |
| LUMIGAN RC | 02324997 | 0.01 % / W/V | SOLUTION · OPHTHALMIC | ABBVIE CORPORATION |
| PRO-BIMATOPROST RC | 02563428 | 0.01 % / W/V | SOLUTION · OPHTHALMIC | PRO DOC LIMITEE |
| VISTITAN | 02429063 | 0.03 % / W/V | SOLUTION · OPHTHALMIC | SANDOZ CANADA INCORPORATED |
| ZIMED PF | 02533464 | 0.03 % / W/V | SOLUTION · OPHTHALMIC | LUVO MEDICAL TECHNOLOGIES INC |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BIMATOPROST 0.01% EYE DROPS | $42.51553 | per ML | 23 Sep 2026 |
| US NADAC | BIMATOPROST 0.01% EYE DROPS | $43.41341 | per ML | 23 Sep 2026 |
| US NADAC | BIMATOPROST 0.01% EYE DROPS | $42.752 | per ML | 23 Sep 2026 |
| US NADAC | BIMATOPROST 0.03% EYE DROPS | $8.85194 | per ML | 23 Sep 2026 |
| US NADAC | BIMATOPROST 0.03% EYE DROPS | $4.20713 | per ML | 23 Sep 2026 |
| US NADAC | BIMATOPROST 0.03% EYE DROPS | $6.96893 | per ML | 23 Sep 2026 |
| US NADAC | BIMATOPROST 0.03% EYELASH SOLN | $20.64928 | per ML | 23 Sep 2026 |
| US NADAC | BIMATOPROST 0.03% EYELASH SOLN | $26.27422 | per ML | 23 Sep 2026 |
| US NADAC | LATISSE 0.03% EYELASH SOLUTION | $31.49063 | per ML | 23 Sep 2026 |
| US NADAC | LATISSE 0.03% EYELASH SOLUTION | $40.97569 | per ML | 23 Sep 2026 |
| US NADAC | LUMIGAN 0.01% EYE DROPS | $103.06335 | per ML | 23 Sep 2026 |
| US NADAC | LUMIGAN 0.01% EYE DROPS | $102.99002 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Bimatoprost 100micrograms/ml eye drops | £2.42 | 3 ml | 1 Oct 2026 |
| NHS Drug Tariff | Bimatoprost 300micrograms/ml eye drops | £7.67 | 3 ml | 1 Oct 2026 |
| NHS Drug Tariff | Bimatoprost 300micrograms/ml eye drops 0.4ml unit dose preservative free | £13.75 | 30 unit dose | 1 Oct 2026 |
| NHS Drug Tariff | Bimatoprost 300micrograms/ml eye drops preservative free | £9.79 | 3 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.